Skip Navigation
Search Menu
Find an Expert

 

Photo of Dr. Allen Everett

Allen Dale Everett, M.D.

Director of the Pediatric Proteome Center
Professor of Pediatrics

Male

Appointment Phone

410-955-9714

Main Location

The Johns Hopkins Hospital

Out-of-State & International Patients +
Out of State Patients

Call 410-464-6641 (8a.m. to 6p.m., EST, Mon-Fri)

Learn more about our out-of-state patient services »

International Patients

Call +1-410-502-7683 (7a.m. to 6p.m., EST, Mon-Fri)

Learn more about our international patient services »

Titles

  • Director of the Pediatric Proteome Center
  • Professor of Pediatrics

Centers & Institutes

Departments

Locations

The Johns Hopkins Hospital

Appointment Phone: 410-955-9714

600 N. Wolfe Street
Ross Research Building 1114A
Baltimore, MD 21287 map
Phone: 410-955-5987
Fax: 410-055-0897

Expertise

Cardiology , Congenital Heart Disease - Pediatric, Pediatric Cardiology

Research Interests

Biomarkers of pulmonary hypertension and brain injury; Cardiac Catheterization Outcomes and Quality; Computer Modeling of Congenital Aortic Disease; Bioinformatics

Biography

Dr. Allen Everett is a professor of pediatrics at the Johns Hopkins University School of Medicine. His areas of clinical expertise include vascular injury, proteomics, biomarker discovery of vascular disease, and cardiac catheterization outcomes and quality measures. Dr. Everett also serves as the director of the Pediatric Proteome Center.

Dr. Everett earned his M.D. from East Tennessee State University. He completed his residency in pediatrics at University of Virginia Health System and performed a fellowship in pediatric cardiology at University of Virginia. Dr. Everett joined the Johns Hopkins faculty in 2003.

He has become the program leader at Johns Hopkins in pediatric biomarker discovery, initially in sickle cell disease and subsequently in other pediatric clinical conditions (birth injury, congenital heart disease repair, ECMO, prematurity and pulmonary hypertension). He is the principal investigator (PI) or co-PI on multiple NIH- funded R01 studies and two proteomic-focused contracts for the NICHD National Children’s Study.

Dr. Everett is an author of 69 peer review papers, two book chapters, editor/author of two books and associate editor for two journals, Cardiology in the Young and PROTEOMICS Clinical Applications. He is a co-developer of PedCathTM cardiac catheterization software with Scientific Software Solutions which has been translated into five languages, has five US biomarker patents filed and brain injury biomarkers licensed to ImmunArray, Ltd., for which he is a consultant.

...read more

Featured Video

Patient Care and Research

    Additional Information

  • Education +

    Degrees

    • East Tennessee State University / MD (1984)

    Residencies

    • University of Virginia Health System / Pediatrics (1987)

    Fellowships

    • University of Virginia Health System / Pediatric Cardiology (1991)

    Certifications

    • American Board of Pediatrics / Pediatric Cardiology (1991, 2013)
  • Research & Publications +

    Research Summary

    Dr. Everett has become the program leader at Johns Hopkins in pediatric biomarker discovery, initially in sickle cell disease and subsequently in other pediatric clinical conditions (birth injury, congenital heart disease repair, ECMO, prematurity and pulmonary hypertension).

    He is the principal investigator (PI) or co-PI on multiple NIH- funded R01 studies and two proteomic focused contracts for the NICHD National Children’s Study.

    Selected Publications View all on PubMed

    Everett A, Ignjatovic V. "Paediatrics and proteomics: back to the beginning." Proteomics Clin Appl. 2014 Dec;8(11-12):805-6. doi: 10.1002/prca.201470064.

    Goldenberg NA, Everett AD, Graham D, Bernard TJ, Nowak-Göttl U. "Proteomic and other mass spectrometry based "omics" biomarker discovery and validation in pediatric venous thromboembolism and arterial ischemic stroke: current state, unmet needs, and future directions." Proteomics Clin Appl. 2014 Dec;8(11-12):828-36. doi: 10.1002/prca.201400062.

    Nies MK, Ivy DD, Everett AD. "The untapped potential of proteomic analysis in pediatric pulmonary hypertension." Proteomics Clin Appl. 2014 Dec;8(11-12):862-74. doi:

    Lance EI, Casella JF, Everett AD, Barron-Casella E. "Proteomic and biomarker studies and neurological complications of pediatric sickle cell disease." Proteomics Clin Appl. 2014

    Laflam A, Joshi B, Brady K, Yenokyan G, Brown C, Everett A, Selnes O, McFarland E, Hogue CW. "Shoulder surgery in the beach chair position is associated with diminished cerebral autoregulation but no differences in postoperative cognition or brain injury biomarker levels compared with supine positioning: the anesthesia patient safety foundation beach chair study." Anesth Analg. 2015 Jan;120(1):176-85. doi: 10.1213/ANE.0000000000000455.

    Patents

    A Multi-protein Biomarker Assay for Brain Injury Detection and Outcome
    Patent # WO2015009907 A1 | 01/22/2015

    The present invention relates to the field of brain injuries. More specifically, the present invention provides methods and compositions useful in the diagnosis/prognosis/assessment of brain injuries. In a specific embodiment, a method for identifying which patients with traumatic brain injury (TBI) require a head computerized tomography (CT) scan for diagnosing acute intracranial pathology comprises the steps of (a) obtaining or collecting a sample from the patient; (b) measuring the levels of one or more biomarkers in the blood sample obtained from the patient, wherein the biomarkers comprise glial fibrillary acidic protein (GFAP), S100B, metallothionein 3 (MT3), neuron specific enolase (NSE) and intracellular adhesion molecule 5 (ICAM5); and (c) identifying the patient as requiring or not requiring a head CT scan based on the measured levels of one or more of biomarkers comprising GFAP, S100B, MT3, NSE and ICAM5.

    Biosensor Systems and Related Methods for Detecting Analytes in Aqueous and Biological Environments
    Patent # US20140349005 A1 | 11/27/2014

    Disclosed herein are biosensor systems and related methods for detecting analytes in aqueous and biologic environments. A biosensor system for detecting binding of an analyte of interest may include a detector configured to detect a change in an electrical property on a surface thereof. The detector may be a FET. The system also may include a passive layer disposed on a top surface of the detector. Further, the system may include a hydrophobic layer disposed on the passive layer. The system also may include a receptor-attachment material configured for binding to an analyte. A receptor may bind to the analyte, and the receptor may be attached to the receptor-attachment material. The binding of the analyte to the receptor can cause the change of the electrical property at the surface. In response to the change for example, a current may change for indicating the binding of the analyte to the receptor.

    Assay Reagents for a Neurogranin Diagnostic Kit
    Patent # US20140141458 A1 | 05/22/2014

    The present invention relates to the field of biomarkers. More specifically, the present invention relates to assay reagents useful in detecting neurogranin. In a specific embodiment, the present invention provides an isolated antibody or fragment thereof that specifically binds to neurogranin. In another embodiment, the present invention provides a polynucleotide aptamer that specifically binds neurogranin.

    Assay Reagents for a Neurogranin Diagnostic Kit
    Patent # EP2707389 A2 | 03/19/2014

    The present invention relates to the field of biomarkers. More specifically, the present invention relates to assay reagents useful in detecting neurogranin. In a specific embodiment, the present invention provides an isolated antibody or fragment thereof that specifically binds to neurogranin. In another embodiment, the present invention provides a polynucleotide aptamer that specifically binds neurogranin.

    Biomarkers of Pulmonary Hypertension
    Patent # WO2013090811 A1 | 06/20/2013

    Methods are disclosed for predicting or diagnosing pulmonary artery hypertension (PAH) and for determining the efficacy of PAH therapy using biomarkers.

  • Academic Affiliations & Courses +
  • Activities & Honors +

    Professional Activities

    • Associate editor, Cardiology in the Young
    • Associate editor, PROTEOMICS Clinical Applications
    • Co-developer, PedCathTM cardiac catheterization software, Scientific Software Solutions
  • Videos & Media +
Is This You? Edit Profile